Skip to content

ULTRAGENYX PHARMACEUTICAL INC.

RARE

CIK 0001515673

← back to feed
Revenue (TTM)
$601.43M
+20.2% YoY Q1 May 2026
Net Income (TTM)
−$631.36M
−1.1% YoY Q1 May 2026
EPS Diluted (TTM)
−$6.39
+7.3% YoY Q1 May 2026
Gross Margin
99.7%
Q1 May 2026
Operating Margin
-98.2%
Q1 May 2026
Net Margin
-105.0%
Q1 May 2026
Free Cash Flow (TTM)
−$740.84M
Q1 May 2026
Cash
$175M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
98.49M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings